Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 786708, 6 pages
http://dx.doi.org/10.1155/2015/786708
Research Article

Serum Chemerin Levels in relation to Osteoporosis and Bone Mineral Density: A Case-Control Study

1Department of Orthopedics, Jintan Hospital, Jiangsu University, Jintan 213200, China
2College of Medicine, Zhejiang University, Hangzhou 310058, China

Received 18 May 2015; Revised 3 June 2015; Accepted 8 June 2015

Academic Editor: Robert Pichler

Copyright © 2015 Jing He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Waki and P. Tontonoz, “Endocrine functions of adipose tissue,” Annual Review of Pathology: Mechanisms of Disease, vol. 2, no. 1, pp. 31–56, 2007. View at Publisher · View at Google Scholar
  2. G. Musso, E. Paschetta, R. Gambino, M. Cassader, and F. Molinaro, “Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver,” Trends in Molecular Medicine, vol. 19, no. 9, pp. 522–535, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. X. X. Chen and T. Yang, “Roles of leptin in bone metabolism and bone diseases,” Journal of Bone and Mineral Metabolism, 2015. View at Publisher · View at Google Scholar
  4. G. Hipmair, N. Böhler, W. Maschek et al., “Serum leptin is correlated to high turnover in osteoporosis,” Neuroendocrinology Letters, vol. 31, no. 1, pp. 155–160, 2010. View at Google Scholar · View at Scopus
  5. I. Iwamoto, T. Douchi, S. Kosha, M. Murakami, T. Fujino, and Y. Nagata, “Relationships between serum leptin level and regional bone mineral density, bone metabolic markers in healthy women,” Acta Obstetricia et Gynecologica Scandinavica, vol. 79, no. 12, pp. 1060–1064, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Lubkowska, A. Dobek, J. Mieszkowski, W. Garczynski, and D. Chlubek, “Adiponectin as a biomarker of osteoporosis in postmenopausal women: controversies,” Disease Markers, vol. 2014, Article ID 975178, 14 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Biver, C. Salliot, C. Combescure et al., “Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 9, pp. 2703–2713, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Mohiti-Ardekani, H. Soleymani-Salehabadi, M. B. Owlia, and A. Mohiti, “Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients,” Journal of Bone and Mineral Metabolism, vol. 32, no. 4, pp. 400–404, 2014. View at Publisher · View at Google Scholar
  9. S.-G. Roh, S.-H. Song, K.-C. Choi et al., “Chemerin—a new adipokine that modulates adipogenesis via its own receptor,” Biochemical and Biophysical Research Communications, vol. 362, no. 4, pp. 1013–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. K. B. Goralski, T. C. McCarthy, E. A. Hanniman et al., “Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism,” The Journal of Biological Chemistry, vol. 282, no. 38, pp. 28175–28188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Kukla, K. Zwirska-Korczala, M. Hartleb et al., “Serum chemerin and vaspin in non-alcoholic fatty liver disease,” Scandinavian Journal of Gastroenterology, vol. 45, no. 2, pp. 235–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Yilmaz, O. Yonal, R. Kurt et al., “Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease,” Scandinavian Journal of Gastroenterology, vol. 46, no. 1, pp. 91–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Ye, S. Wang, Z. Yang et al., “Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease,” Molecular Biology Reports, vol. 41, no. 3, pp. 1317–1323, 2014. View at Publisher · View at Google Scholar
  14. K. Bozaoglu, K. Bolton, J. McMillan et al., “Chemerin is a novel adipokine associated with obesity and metabolic syndrome,” Endocrinology, vol. 148, no. 10, pp. 4687–4694, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Ozdemir and M. Uçar, “Standardization of spine and hip BMD measurements in different DXA devices,” European Journal of Radiology, vol. 62, no. 3, pp. 423–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Osteaux and O. Louis, “Standardization of bone mineral density measurements and the European multicentre studies,” European Journal of Radiology, vol. 20, no. 3, pp. 170–172, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Lunt, D. Felsenberg, J. Adams et al., “Population-based geographic variations in DXA bone density in Europe: the EVOS study,” Osteoporosis International, vol. 7, no. 3, pp. 175–189, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. E. A. Perez, R. G. Josse, K. I. Pritchard et al., “Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17,” Journal of Clinical Oncology, vol. 24, no. 22, pp. 3629–3635, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. K. Jeon, J. G. Lee, S. S. Kim et al., “Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women,” Endocrine Journal, vol. 58, no. 2, pp. 87–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Yilmaz, “Review article: non-alcoholic fatty liver disease and osteoporosis—clinical and molecular crosstalk,” Alimentary Pharmacology and Therapeutics, vol. 36, no. 4, pp. 345–352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. S. Moon, Y. S. Lee, and S. W. Kim, “Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women,” Endocrine, vol. 42, no. 2, pp. 423–429, 2012. View at Publisher · View at Google Scholar
  22. M. Li, Y. Xu, M. Xu et al., “Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 6, pp. 2033–2038, 2012. View at Publisher · View at Google Scholar
  23. M. J. Armstrong, L. A. Adams, A. Canbay, and W.-K. Syn, “Extrahepatic complications of nonalcoholic fatty liver disease,” Hepatology, vol. 59, no. 3, pp. 1174–1197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Loria, A. Lonardo, L. Carulli et al., “Review article: the metabolic syndrome and non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 22, supplement2, pp. 31–36, 2005. View at Google Scholar · View at Scopus
  25. N. Napoli, R. Strollo, D. Sprini, E. Maddaloni, G. B. Rini, and E. Carmina, “Serum 25-OH vitamin D in relation to bone mineral density and bone turnover,” International Journal of Endocrinology, vol. 2014, Article ID 487463, 5 pages, 2014. View at Publisher · View at Google Scholar
  26. S. Sharma, V. Tandon, S. Mahajan, V. Mahajan, and A. Mahajan, “Obesity: friend or foe for osteoporosis,” Journal of Mid-Life Health, vol. 5, no. 1, pp. 6–9, 2014. View at Publisher · View at Google Scholar
  27. S. Muruganandan and C. J. Sinal, “The impact of bone marrow adipocytes on osteoblast and osteoclast differentiation,” IUBMB Life, vol. 66, no. 3, pp. 147–155, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. K. W. Oh, W. Y. Lee, E. J. Rhee et al., “The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men,” Clinical Endocrinology, vol. 63, no. 2, pp. 131–138, 2005. View at Publisher · View at Google Scholar